PMC:7253482 / 24455-24780 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"804","span":{"begin":86,"end":87},"obj":"Gene"},{"id":"805","span":{"begin":309,"end":310},"obj":"Gene"},{"id":"807","span":{"begin":18,"end":28},"obj":"Species"},{"id":"808","span":{"begin":51,"end":61},"obj":"Species"},{"id":"809","span":{"begin":223,"end":240},"obj":"Species"},{"id":"813","span":{"begin":207,"end":214},"obj":"Chemical"},{"id":"816","span":{"begin":33,"end":37},"obj":"Disease"},{"id":"817","span":{"begin":128,"end":132},"obj":"Disease"},{"id":"818","span":{"begin":304,"end":308},"obj":"Disease"}],"attributes":[{"id":"A804","pred":"tao:has_database_id","subj":"804","obj":"Gene:43740575"},{"id":"A805","pred":"tao:has_database_id","subj":"805","obj":"Gene:43740568"},{"id":"A807","pred":"tao:has_database_id","subj":"807","obj":"Tax:2697049"},{"id":"A808","pred":"tao:has_database_id","subj":"808","obj":"Tax:2697049"},{"id":"A809","pred":"tao:has_database_id","subj":"809","obj":"Tax:2697049"},{"id":"A813","pred":"tao:has_database_id","subj":"813","obj":"MESH:D011134"},{"id":"A816","pred":"tao:has_database_id","subj":"816","obj":"MESH:D045169"},{"id":"A817","pred":"tao:has_database_id","subj":"817","obj":"MESH:D045169"},{"id":"A818","pred":"tao:has_database_id","subj":"818","obj":"MESH:D045169"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"proteins from the SARS-CoV-2 and SARS (SI Fig. 6). SARS-CoV-2 possesses a total of 22 N-linked glycan sites compared with 23 on SARS, with 18 of these sites being in common. As such, it is likely that these glycans on this novel coronavirus would shield similar immunogenic epitopes that are observed on SARS S. As expected, "}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T139","span":{"begin":0,"end":8},"obj":"Body_part"}],"attributes":[{"id":"A139","pred":"fma_id","subj":"T139","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"proteins from the SARS-CoV-2 and SARS (SI Fig. 6). SARS-CoV-2 possesses a total of 22 N-linked glycan sites compared with 23 on SARS, with 18 of these sites being in common. As such, it is likely that these glycans on this novel coronavirus would shield similar immunogenic epitopes that are observed on SARS S. As expected, "}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T79","span":{"begin":18,"end":26},"obj":"Disease"},{"id":"T80","span":{"begin":18,"end":22},"obj":"Disease"},{"id":"T81","span":{"begin":33,"end":37},"obj":"Disease"},{"id":"T82","span":{"begin":51,"end":59},"obj":"Disease"},{"id":"T83","span":{"begin":51,"end":55},"obj":"Disease"},{"id":"T84","span":{"begin":128,"end":132},"obj":"Disease"},{"id":"T85","span":{"begin":304,"end":308},"obj":"Disease"}],"attributes":[{"id":"A79","pred":"mondo_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A80","pred":"mondo_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A81","pred":"mondo_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A82","pred":"mondo_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A83","pred":"mondo_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A84","pred":"mondo_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A85","pred":"mondo_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"proteins from the SARS-CoV-2 and SARS (SI Fig. 6). SARS-CoV-2 possesses a total of 22 N-linked glycan sites compared with 23 on SARS, with 18 of these sites being in common. As such, it is likely that these glycans on this novel coronavirus would shield similar immunogenic epitopes that are observed on SARS S. As expected, "}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T150","span":{"begin":72,"end":73},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T151","span":{"begin":83,"end":85},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T152","span":{"begin":139,"end":141},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"}],"text":"proteins from the SARS-CoV-2 and SARS (SI Fig. 6). SARS-CoV-2 possesses a total of 22 N-linked glycan sites compared with 23 on SARS, with 18 of these sites being in common. As such, it is likely that these glycans on this novel coronavirus would shield similar immunogenic epitopes that are observed on SARS S. As expected, "}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T243","span":{"begin":0,"end":8},"obj":"Chemical"},{"id":"T244","span":{"begin":39,"end":41},"obj":"Chemical"},{"id":"T245","span":{"begin":207,"end":214},"obj":"Chemical"}],"attributes":[{"id":"A243","pred":"chebi_id","subj":"T243","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A244","pred":"chebi_id","subj":"T244","obj":"http://purl.obolibrary.org/obo/CHEBI_90326"},{"id":"A245","pred":"chebi_id","subj":"T245","obj":"http://purl.obolibrary.org/obo/CHEBI_18154"}],"text":"proteins from the SARS-CoV-2 and SARS (SI Fig. 6). SARS-CoV-2 possesses a total of 22 N-linked glycan sites compared with 23 on SARS, with 18 of these sites being in common. As such, it is likely that these glycans on this novel coronavirus would shield similar immunogenic epitopes that are observed on SARS S. As expected, "}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T72","span":{"begin":102,"end":107},"obj":"http://purl.obolibrary.org/obo/BFO_0000029"},{"id":"T73","span":{"begin":151,"end":156},"obj":"http://purl.obolibrary.org/obo/BFO_0000029"}],"text":"proteins from the SARS-CoV-2 and SARS (SI Fig. 6). SARS-CoV-2 possesses a total of 22 N-linked glycan sites compared with 23 on SARS, with 18 of these sites being in common. As such, it is likely that these glycans on this novel coronavirus would shield similar immunogenic epitopes that are observed on SARS S. As expected, "}

{"project":"LitCovid-sample-Enju","denotations":[{"id":"T18965","span":{"begin":0,"end":8},"obj":"NNS"},{"id":"T72137","span":{"begin":9,"end":13},"obj":"IN"},{"id":"T71306","span":{"begin":14,"end":17},"obj":"DT"},{"id":"T25653","span":{"begin":18,"end":28},"obj":"NN"},{"id":"T82634","span":{"begin":29,"end":32},"obj":"CC"},{"id":"T90138","span":{"begin":33,"end":37},"obj":"NN"},{"id":"T79086","span":{"begin":38,"end":39},"obj":"-LRB-"},{"id":"T21819","span":{"begin":39,"end":41},"obj":"NN"},{"id":"T4098","span":{"begin":42,"end":48},"obj":"NN"},{"id":"T37852","span":{"begin":48,"end":49},"obj":"-RRB-"},{"id":"T34122","span":{"begin":51,"end":61},"obj":"NN"},{"id":"T47078","span":{"begin":62,"end":71},"obj":"VBZ"},{"id":"T64573","span":{"begin":72,"end":73},"obj":"DT"},{"id":"T60437","span":{"begin":74,"end":79},"obj":"NN"},{"id":"T28667","span":{"begin":80,"end":82},"obj":"IN"},{"id":"T12092","span":{"begin":83,"end":85},"obj":"CD"},{"id":"T1640","span":{"begin":86,"end":94},"obj":"JJ"},{"id":"T97157","span":{"begin":95,"end":101},"obj":"NN"},{"id":"T11869","span":{"begin":102,"end":107},"obj":"NNS"},{"id":"T81728","span":{"begin":108,"end":116},"obj":"VBN"},{"id":"T53746","span":{"begin":117,"end":121},"obj":"IN"},{"id":"T64999","span":{"begin":122,"end":124},"obj":"CD"},{"id":"T3044","span":{"begin":125,"end":127},"obj":"IN"},{"id":"T27983","span":{"begin":128,"end":132},"obj":"NNP"},{"id":"T70372","span":{"begin":132,"end":133},"obj":"-COMMA-"},{"id":"T36523","span":{"begin":134,"end":138},"obj":"IN"},{"id":"T81512","span":{"begin":139,"end":141},"obj":"CD"},{"id":"T55641","span":{"begin":142,"end":144},"obj":"IN"},{"id":"T31809","span":{"begin":145,"end":150},"obj":"DT"},{"id":"T30346","span":{"begin":151,"end":156},"obj":"NNS"},{"id":"T33229","span":{"begin":157,"end":162},"obj":"VBG"},{"id":"T95497","span":{"begin":163,"end":165},"obj":"IN"},{"id":"T81137","span":{"begin":166,"end":172},"obj":"NN"},{"id":"T99058","span":{"begin":174,"end":176},"obj":"IN"},{"id":"T67481","span":{"begin":177,"end":181},"obj":"JJ"},{"id":"T5512","span":{"begin":181,"end":182},"obj":"-COMMA-"},{"id":"T56317","span":{"begin":183,"end":185},"obj":"PRP"},{"id":"T83032","span":{"begin":186,"end":188},"obj":"VBZ"},{"id":"T6892","span":{"begin":189,"end":195},"obj":"JJ"},{"id":"T46550","span":{"begin":196,"end":200},"obj":"IN"},{"id":"T32694","span":{"begin":201,"end":206},"obj":"DT"},{"id":"T45067","span":{"begin":207,"end":214},"obj":"NNS"},{"id":"T82922","span":{"begin":215,"end":217},"obj":"IN"},{"id":"T78450","span":{"begin":218,"end":222},"obj":"DT"},{"id":"T70467","span":{"begin":223,"end":228},"obj":"JJ"},{"id":"T54943","span":{"begin":229,"end":240},"obj":"NN"},{"id":"T82041","span":{"begin":241,"end":246},"obj":"MD"},{"id":"T38496","span":{"begin":247,"end":253},"obj":"VB"},{"id":"T40453","span":{"begin":254,"end":261},"obj":"JJ"},{"id":"T78152","span":{"begin":262,"end":273},"obj":"JJ"},{"id":"T36034","span":{"begin":274,"end":282},"obj":"NNS"},{"id":"T43430","span":{"begin":283,"end":287},"obj":"WDT"},{"id":"T42643","span":{"begin":288,"end":291},"obj":"VBP"},{"id":"T34663","span":{"begin":292,"end":300},"obj":"VBN"},{"id":"T28338","span":{"begin":301,"end":303},"obj":"IN"},{"id":"T42537","span":{"begin":304,"end":308},"obj":"NNP"},{"id":"T28404","span":{"begin":309,"end":311},"obj":"NNP"},{"id":"T34718","span":{"begin":312,"end":314},"obj":"IN"},{"id":"T3102","span":{"begin":315,"end":323},"obj":"VBN"},{"id":"T14875","span":{"begin":323,"end":324},"obj":"-COMMA-"}],"relations":[{"id":"R47619","pred":"arg1Of","subj":"T18965","obj":"T72137"},{"id":"R67544","pred":"arg2Of","subj":"T25653","obj":"T72137"},{"id":"R10275","pred":"arg1Of","subj":"T25653","obj":"T71306"},{"id":"R92973","pred":"arg1Of","subj":"T18965","obj":"T82634"},{"id":"R46838","pred":"arg2Of","subj":"T90138","obj":"T82634"},{"id":"R33151","pred":"arg1Of","subj":"T90138","obj":"T79086"},{"id":"R76672","pred":"arg2Of","subj":"T4098","obj":"T79086"},{"id":"R23030","pred":"arg3Of","subj":"T37852","obj":"T79086"},{"id":"R7891","pred":"arg1Of","subj":"T4098","obj":"T21819"},{"id":"R90066","pred":"arg1Of","subj":"T34122","obj":"T47078"},{"id":"R2421","pred":"arg2Of","subj":"T60437","obj":"T47078"},{"id":"R69986","pred":"arg1Of","subj":"T60437","obj":"T64573"},{"id":"R89049","pred":"arg1Of","subj":"T60437","obj":"T28667"},{"id":"R56835","pred":"arg2Of","subj":"T11869","obj":"T28667"},{"id":"R66944","pred":"arg1Of","subj":"T11869","obj":"T12092"},{"id":"R97186","pred":"arg1Of","subj":"T11869","obj":"T1640"},{"id":"R70039","pred":"arg1Of","subj":"T11869","obj":"T97157"},{"id":"R58702","pred":"arg1Of","subj":"T47078","obj":"T81728"},{"id":"R79993","pred":"arg2Of","subj":"T53746","obj":"T81728"},{"id":"R73081","pred":"arg2Of","subj":"T64999","obj":"T53746"},{"id":"R25678","pred":"arg1Of","subj":"T81728","obj":"T3044"},{"id":"R54442","pred":"arg2Of","subj":"T27983","obj":"T3044"},{"id":"R43596","pred":"arg1Of","subj":"T47078","obj":"T70372"},{"id":"R85039","pred":"arg1Of","subj":"T47078","obj":"T36523"},{"id":"R48982","pred":"arg2Of","subj":"T81512","obj":"T36523"},{"id":"R44430","pred":"arg3Of","subj":"T33229","obj":"T36523"},{"id":"R73216","pred":"arg1Of","subj":"T81512","obj":"T55641"},{"id":"R99688","pred":"arg2Of","subj":"T30346","obj":"T55641"},{"id":"R80985","pred":"arg1Of","subj":"T30346","obj":"T31809"},{"id":"R33403","pred":"arg1Of","subj":"T81512","obj":"T33229"},{"id":"R77630","pred":"arg2Of","subj":"T95497","obj":"T33229"},{"id":"R12152","pred":"arg1Of","subj":"T81512","obj":"T95497"},{"id":"R49729","pred":"arg2Of","subj":"T81137","obj":"T95497"},{"id":"R71487","pred":"arg1Of","subj":"T83032","obj":"T99058"},{"id":"R45768","pred":"arg2Of","subj":"T67481","obj":"T99058"},{"id":"R85204","pred":"arg1Of","subj":"T83032","obj":"T5512"},{"id":"R51225","pred":"arg2Of","subj":"T6892","obj":"T83032"},{"id":"R54673","pred":"arg2Of","subj":"T38496","obj":"T6892"},{"id":"R58371","pred":"arg1Of","subj":"T38496","obj":"T46550"},{"id":"R42340","pred":"arg1Of","subj":"T45067","obj":"T32694"},{"id":"R72305","pred":"arg1Of","subj":"T45067","obj":"T82922"},{"id":"R86649","pred":"arg2Of","subj":"T54943","obj":"T82922"},{"id":"R67963","pred":"arg1Of","subj":"T54943","obj":"T78450"},{"id":"R72941","pred":"arg1Of","subj":"T54943","obj":"T70467"},{"id":"R41744","pred":"arg1Of","subj":"T45067","obj":"T82041"},{"id":"R65080","pred":"arg2Of","subj":"T38496","obj":"T82041"},{"id":"R36276","pred":"arg1Of","subj":"T45067","obj":"T38496"},{"id":"R65730","pred":"arg2Of","subj":"T36034","obj":"T38496"},{"id":"R11713","pred":"arg1Of","subj":"T36034","obj":"T40453"},{"id":"R37452","pred":"arg1Of","subj":"T36034","obj":"T78152"},{"id":"R67493","pred":"arg1Of","subj":"T36034","obj":"T43430"},{"id":"R68310","pred":"arg1Of","subj":"T36034","obj":"T42643"},{"id":"R78256","pred":"arg2Of","subj":"T34663","obj":"T42643"},{"id":"R11906","pred":"arg2Of","subj":"T36034","obj":"T34663"},{"id":"R84232","pred":"arg3Of","subj":"T34718","obj":"T34663"},{"id":"R67918","pred":"arg1Of","subj":"T34663","obj":"T28338"},{"id":"R26118","pred":"arg2Of","subj":"T28404","obj":"T28338"},{"id":"R80995","pred":"arg1Of","subj":"T28404","obj":"T42537"},{"id":"R94455","pred":"arg2Of","subj":"T3102","obj":"T34718"}],"text":"proteins from the SARS-CoV-2 and SARS (SI Fig. 6). SARS-CoV-2 possesses a total of 22 N-linked glycan sites compared with 23 on SARS, with 18 of these sites being in common. As such, it is likely that these glycans on this novel coronavirus would shield similar immunogenic epitopes that are observed on SARS S. As expected, "}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T138","span":{"begin":0,"end":8},"obj":"Body_part"}],"attributes":[{"id":"A138","pred":"fma_id","subj":"T138","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"proteins from the SARS-CoV-2 and SARS (SI Fig. 6). SARS-CoV-2 possesses a total of 22 N-linked glycan sites compared with 23 on SARS, with 18 of these sites being in common. As such, it is likely that these glycans on this novel coronavirus would shield similar immunogenic epitopes that are observed on SARS S. As expected, "}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T165","span":{"begin":0,"end":8},"obj":"Chemical"},{"id":"T166","span":{"begin":207,"end":214},"obj":"Chemical"}],"attributes":[{"id":"A165","pred":"chebi_id","subj":"T165","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A166","pred":"chebi_id","subj":"T166","obj":"http://purl.obolibrary.org/obo/CHEBI_18154"}],"text":"proteins from the SARS-CoV-2 and SARS (SI Fig. 6). SARS-CoV-2 possesses a total of 22 N-linked glycan sites compared with 23 on SARS, with 18 of these sites being in common. As such, it is likely that these glycans on this novel coronavirus would shield similar immunogenic epitopes that are observed on SARS S. As expected, "}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T169","span":{"begin":18,"end":28},"obj":"Species"},{"id":"T170","span":{"begin":18,"end":22},"obj":"Species"},{"id":"T171","span":{"begin":33,"end":37},"obj":"Species"},{"id":"T172","span":{"begin":51,"end":61},"obj":"Species"},{"id":"T173","span":{"begin":51,"end":55},"obj":"Species"},{"id":"T174","span":{"begin":128,"end":132},"obj":"Species"},{"id":"T175","span":{"begin":304,"end":308},"obj":"Species"}],"attributes":[{"id":"A169","pred":"ncbi_taxonomy_id","subj":"T169","obj":"NCBItxid:2697049"},{"id":"A170","pred":"ncbi_taxonomy_id","subj":"T170","obj":"NCBItxid:694009"},{"id":"A171","pred":"ncbi_taxonomy_id","subj":"T171","obj":"NCBItxid:694009"},{"id":"A172","pred":"ncbi_taxonomy_id","subj":"T172","obj":"NCBItxid:2697049"},{"id":"A173","pred":"ncbi_taxonomy_id","subj":"T173","obj":"NCBItxid:694009"},{"id":"A174","pred":"ncbi_taxonomy_id","subj":"T174","obj":"NCBItxid:694009"},{"id":"A175","pred":"ncbi_taxonomy_id","subj":"T175","obj":"NCBItxid:694009"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"proteins from the SARS-CoV-2 and SARS (SI Fig. 6). SARS-CoV-2 possesses a total of 22 N-linked glycan sites compared with 23 on SARS, with 18 of these sites being in common. As such, it is likely that these glycans on this novel coronavirus would shield similar immunogenic epitopes that are observed on SARS S. As expected, "}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T138","span":{"begin":51,"end":173},"obj":"Sentence"},{"id":"T139","span":{"begin":174,"end":311},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"proteins from the SARS-CoV-2 and SARS (SI Fig. 6). SARS-CoV-2 possesses a total of 22 N-linked glycan sites compared with 23 on SARS, with 18 of these sites being in common. As such, it is likely that these glycans on this novel coronavirus would shield similar immunogenic epitopes that are observed on SARS S. As expected, "}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T74","span":{"begin":18,"end":28},"obj":"Disease"},{"id":"T75","span":{"begin":18,"end":22},"obj":"Disease"},{"id":"T76","span":{"begin":33,"end":37},"obj":"Disease"},{"id":"T77","span":{"begin":51,"end":61},"obj":"Disease"},{"id":"T78","span":{"begin":51,"end":55},"obj":"Disease"},{"id":"T79","span":{"begin":128,"end":132},"obj":"Disease"},{"id":"T80","span":{"begin":304,"end":308},"obj":"Disease"}],"attributes":[{"id":"A74","pred":"mondo_id","subj":"T74","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A75","pred":"mondo_id","subj":"T75","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A76","pred":"mondo_id","subj":"T76","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A77","pred":"mondo_id","subj":"T77","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A78","pred":"mondo_id","subj":"T78","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A79","pred":"mondo_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A80","pred":"mondo_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"proteins from the SARS-CoV-2 and SARS (SI Fig. 6). SARS-CoV-2 possesses a total of 22 N-linked glycan sites compared with 23 on SARS, with 18 of these sites being in common. As such, it is likely that these glycans on this novel coronavirus would shield similar immunogenic epitopes that are observed on SARS S. As expected, "}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"807","span":{"begin":18,"end":28},"obj":"Species"},{"id":"816","span":{"begin":33,"end":37},"obj":"Disease"},{"id":"808","span":{"begin":51,"end":61},"obj":"Species"},{"id":"804","span":{"begin":86,"end":87},"obj":"Gene"},{"id":"817","span":{"begin":128,"end":132},"obj":"Disease"},{"id":"813","span":{"begin":207,"end":214},"obj":"Chemical"},{"id":"809","span":{"begin":223,"end":240},"obj":"Species"},{"id":"818","span":{"begin":304,"end":308},"obj":"Disease"},{"id":"805","span":{"begin":309,"end":310},"obj":"Gene"}],"attributes":[{"id":"A808","pred":"pubann:denotes","subj":"808","obj":"Tax:2697049"},{"id":"A807","pred":"pubann:denotes","subj":"807","obj":"Tax:2697049"},{"id":"A818","pred":"pubann:denotes","subj":"818","obj":"MESH:D045169"},{"id":"A804","pred":"pubann:denotes","subj":"804","obj":"Gene:43740575"},{"id":"A809","pred":"pubann:denotes","subj":"809","obj":"Tax:2697049"},{"id":"A813","pred":"pubann:denotes","subj":"813","obj":"MESH:D011134"},{"id":"A817","pred":"pubann:denotes","subj":"817","obj":"MESH:D045169"},{"id":"A805","pred":"pubann:denotes","subj":"805","obj":"Gene:43740568"},{"id":"A816","pred":"pubann:denotes","subj":"816","obj":"MESH:D045169"}],"text":"proteins from the SARS-CoV-2 and SARS (SI Fig. 6). SARS-CoV-2 possesses a total of 22 N-linked glycan sites compared with 23 on SARS, with 18 of these sites being in common. As such, it is likely that these glycans on this novel coronavirus would shield similar immunogenic epitopes that are observed on SARS S. As expected, "}

{"project":"LitCovid-sentences","denotations":[{"id":"T138","span":{"begin":51,"end":173},"obj":"Sentence"},{"id":"T139","span":{"begin":174,"end":311},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"proteins from the SARS-CoV-2 and SARS (SI Fig. 6). SARS-CoV-2 possesses a total of 22 N-linked glycan sites compared with 23 on SARS, with 18 of these sites being in common. As such, it is likely that these glycans on this novel coronavirus would shield similar immunogenic epitopes that are observed on SARS S. As expected, "}